An assessment of the role of reactive oxygen species and redox signaling in norepinephrine-induced apoptosis and hypertrophy of H9c2 cardiac myoblasts.
Cardiac myocytes, upon exposure to increasing doses of norepinephrine (NE), transit from hypertrophic to apoptotic phenotype. Since reactive oxygen species (ROS) generation is attributed to both phenomena, the authors tested whether an elevation in intracellular ROS level causes such transition. H9c2 cardiac myoblasts upon treatment with hypertrophic and apoptotic doses of NE (2 and 100 microM, respectively) transiently induced intracellular ROS at a comparable level, while 200 microM H(2)O(2), another proapoptotic agonist, showed robust and sustained ROS generation. Upon analysis of a number of redox-responsive transcription factors as the downstream targets of ROS signaling, the authors observed that NE (2 and 100 microM) and H(2)O(2) (200 microM) were ineffective in inducing NF-kappaB while both the agonists upregulated AP-1 and Nrf-2. However, the extents of induction of AP-1 and Nrf-2 were not in direct correlation with the respective ROS levels. Also, AP-1 activities induced by two doses of NE were intrinsically different, since at 2 microM, it primarily induced FosB, and at 100 microM it activated Fra-1. Differential induction of FosB and Fra-1 was also reiterated in adult rat myocardium injected with increasing doses of NE. Therefore, NE induces hypertrophy and apoptosis in cardiac myocytes by distinct redox-signaling rather than a general surge of ROS.
Gupta
Manveen K
MK
Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India.
Neelakantan
T V
TV
Sanghamitra
Mishra
M
Tyagi
Rakesh K
RK
Dinda
Amit
A
Maulik
Subir
S
Mukhopadhyay
Chinmay K
CK
Goswami
Shyamal K
SK
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D002460:Cell Line; D017930:Genes, Reporter; D006861:Hydrogen Peroxide / Q000494:pharmacology; D006984:Hypertrophy / Q000139:chemically induced*; D008297:Male; D032386:Myoblasts, Cardiac / Q000166:cytology / Q000187:drug effects; D009206:Myocardium / Q000166:cytology / Q000473:pathology; D051267:NF-E2-Related Factor 2 / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D009638:Norepinephrine / Q000494:pharmacology*; D016761:Oncogene Proteins v-fos / Q000378:metabolism; D016877:Oxidants / Q000494:pharmacology; D010084:Oxidation-Reduction; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*; D018808:Transcription Factor AP-1 / Q000378:metabolism
D000316:Adrenergic alpha-Agonists; D051267:NF-E2-Related Factor 2; D016328:NF-kappa B; D016761:Oncogene Proteins v-fos; D016877:Oxidants; D017382:Reactive Oxygen Species; D018808:Transcription Factor AP-1; D006861:Hydrogen Peroxide; D009638:Norepinephrine